Roivant Sciences (ROIV) Retained Earnings (2021 - 2026)
Roivant Sciences' (ROIV) quarterly Retained Earnings came in at -$501.8 million in Q1 2026, down 111.0% YoY from $4.6 billion in Q1 2025, and down 110.15% on a QoQ basis from $4.9 billion in Q4 2025.
Analysis
Roivant Sciences (ROIV) Retained Earnings (2021 - 2026) Analysis & Trends
Roivant Sciences (ROIV) has 6 years of Retained Earnings data on file, last reported at -$501.8 million in Q1 2026.
- Quarterly Retained Earnings fell 111.0% year-over-year to -$501.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$501.8 million (down 111.0% YoY) and the FY2026 annual result came in at -$501.8 million, down 111.0% from the prior year.
- Retained Earnings slipped to -$501.8 million in Q1 2026, from $4.9 billion in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $5.4 billion in Q4 2023 to a low of -$4.4 billion in Q3 2023.
- A 5-year average of $615.6 million and a median of $17.1 million in 2025 frame the typical range for Retained Earnings.
- Annual changes were most pronounced in 2022 — Retained Earnings surged 305894.05% — and 2025, when it plunged 208.48%.
- Tracing ROIV's Retained Earnings over 5 years: stood at -$3.7 billion in 2022, then jumped by 245.68% to $5.4 billion in 2023, then fell by 12.42% to $4.7 billion in 2024, then advanced by 4.72% to $4.9 billion in 2025, then sank by 110.15% to -$501.8 million in 2026.
- The last three Retained Earnings figures came in at -$501.8 million (Q1 2026), $4.9 billion (Q4 2025), and -$429.1 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 5.10 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -4.00 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 13.05 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -6.33 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 4.38 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Roivant Sciences | 25.18 Bn | 25.18 Bn | 1.16 Mn | 5.13 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 5.13 Bn |
| Mar 31, 2026 | 5.02 Bn |
| Dec 31, 2025 | 4.94 Bn |
| Sep 30, 2025 | 4.77 Bn |
| Jun 30, 2025 | 4.64 Bn |
| Mar 31, 2025 | 4.56 Bn |
| Dec 31, 2024 | 4.72 Bn |
| Sep 30, 2024 | 4.78 Bn |
| Jun 30, 2024 | 4.78 Bn |
| Mar 31, 2024 | 5.40 Bn |
| Dec 31, 2023 | 5.39 Bn |
| Sep 30, 2023 | 5.32 Bn |
| Jun 30, 2023 | 4.98 Bn |
| Mar 31, 2023 | 4.93 Bn |
| Dec 31, 2022 | 4.70 Bn |
| Sep 30, 2022 | 4.54 Bn |
| Jun 30, 2022 | 4.47 Bn |
| Mar 31, 2022 | 4.42 Bn |
| Dec 31, 2021 | 4.36 Bn |
| Sep 30, 2021 | 4.25 Bn |